Daenen, K.; Department of Microbiology and Immunology, Laboratory of Nephrology, KU Leuven – University of Leuven, Leuven, 3000, Belgium, Department of Nephrology, Dialysis and Renal Transplantation, University Hospitals Leuven, Leuven, 3000, Belgium, Department of Nephrology, Sahlgrenska University Hospital, Gothenburg, Sweden
Andries, A.; Department of Pharmaceutical and Pharmacological Sciences, Pharmaceutical Analysis, KU Leuven – University of Leuven, Leuven, 3000, Belgium
Mekahli, D.; Department of Development and Regeneration, Laboratory of Pediatrics, PKD Group, KU Leuven – University of Leuven, Leuven, 3000, Belgium, Department of Pediatric Nephrology, University Hospitals Leuven, Leuven, 3000, Belgium
Van Schepdael, A.; Department of Pharmaceutical and Pharmacological Sciences, Pharmaceutical Analysis, KU Leuven – University of Leuven, Leuven, 3000, Belgium
Jouret, François ; Université de Liège - ULiège > Département des sciences cliniques > Néphrologie
Bammens, B.; Department of Microbiology and Immunology, Laboratory of Nephrology, KU Leuven – University of Leuven, Leuven, 3000, Belgium, Department of Nephrology, Dialysis and Renal Transplantation, University Hospitals Leuven, Leuven, 3000, Belgium
Locatelli F, Canaud B, Eckardt K-U, Stenvinkel P, Wanner C, Zoccali C (2003) Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 18:1272–1280
Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O (2012) Oxidative stress and antioxidant defense. World Allergy Organ J 5:9–19
Di Meo S, Reed TT, Venditti P, Victor VM (2016) Role of ROS and RNS sources in physiological and pathological conditions. Oxidative Med Cell Longev 2016:1–44
Che R, Yuan Y, Huang S, Zhang A (2014) Mitochondrial dysfunction in the pathophysiology of renal diseases. AJP Ren Physiol 306:F367–F378
Sureshbabu A, Ryter SW, Choi ME (2015) Oxidative stress and autophagy: crucial modulators of kidney injury. Redox Biol 4:208–214
Himmelfarb J (2005) Relevance of oxidative pathways in the pathophysiology of chronic kidney disease. Cardiol Clin 23:319–330
Popolo A, Autore G, Pinto A, Marzocco S (2013) Oxidative stress in patients with cardiovascular disease and chronic renal failure. Free Radic Res 47:346–356
Sibal L, Agarwal SC, Home PD, Boger RH (2010) The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev 6:82–90
Yu M, Kim YJ, Kang DH (2010) Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress 15. Clin J Am Soc Nephrol
Ward RA, McLeish KR (1995) Polymorphonuclear leukocyte oxidative burst is enhanced in patients with chronic renal insufficiency. J Am Soc Nephrol 5:1697–1702
Tbahriti HF, Kaddous A, Bouchenak M, Mekki K (2013) Effect of different stages of chronic kidney disease and renal replacement therapies on oxidant-antioxidant balance in uremic patients. Biochem Res Int 2013:358985
Jankowska M, Rutkowski B, Dębska-Ślizień A (2017) Vitamins and microelement bioavailability in different stages of chronic kidney disease. Nutrients 9
Stocker R, Keaney JF Jr (2004) Role of oxidative modifications in atherosclerosis. Physiol Rev 84:1381–1478
Czerska M, Mikołajewska K, Zieliński M, Gromadzińska J, Wąsowicz W (2015) Today’s oxidative stress markers. Med Pr 66:393–405
Birben E, Murat U, Md S, Sackesen C, Erzurum S, Kalayci O (2012) Oxidative stress and antioxidant defense. WAO J 5:9–19
Pieczenik SR, Neustadt J (2007) Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol 83:84–92
Brandes RP, Kreuzer J (2005) Vascular NADPH oxidases: molecular mechanisms of activation. Cardiovasc Res 65:16–27
Lambeth JD (2007) Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. Free Radic Biol Med 43:332–347
Chen F, Haigh S, Barman S, Fulton DJ (2012) From form to function: the role of Nox4 in the cardiovascular system. Front Physiol 3:412
Cai H (2005) NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and vascular disease. Circ Res 96:818–822
Förstermann U, Li H (2011) Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling. Br J Pharmacol 164:213–223
Alp NJ, Channon KM (2004) Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol 24:413–420
Yogalingam G, Lee AR, Mackenzie DS, Maures TJ, Rafalko A, Prill H, Berguig GY, Hague C, Christianson T, Bell SM, LeBowitz JH (2017) Cellular uptake and delivery of myeloperoxidase to lysosomes promote lipofuscin degradation and lysosomal stress in retinal cells. J Biol Chem 292:4255–4265
Ray RS, Katyal A (2016) Myeloperoxidase: bridging the gap in neurodegeneration. Neurosci Biobehav Rev 68:611–620
Daugherty A, Dunn JL, Rateri DL, Heinecke JW (1994) Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 94:437–444
Brennan ML, Penn MS, Van LF, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL (2003) Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349:1595–1604
Nicholls SJ, Tang WH, Brennan D, Brennan ML, Mann S, Nissen SE, Hazen SL (2011) Risk prediction with serial myeloperoxidase monitoring in patients with acute chest pain. Clin Chem 57:1762–1770
Chung HY, Baek BS, Song SH, Kim MS, Huh JI, Shim KH, Kim KW, Lee KH (1997) Xanthine dehydrogenase/xanthine oxidase and oxidative stress. Age (Omaha) 20:127–140
Pham-Huy LA, He H, Pham-Huy C (2008) Free radicals, antioxidants in disease and health. Int J Biomed Sci 4:89–96
Fox PL, Mazumder B, Ehrenwald E, Mukhopadhyay CK (2000) Ceruloplasmin and cardiovascular disease. Free Radic Biol Med 28:1735–1744
Ehrenwald E, Fox PL (1996) Role of endogenous ceruloplasmin in low density lipoprotein oxidation by human U937 monocytic cells. J Clin Invest 97:884–890
Ehrenwald E, Chisolm GM, Fox PL (1994) Intact human ceruloplasmin oxidatively modifies low density lipoprotein. J Clin Invest 93:1493–1501
Alam J, Cook JL (2007) How many transcription factors does it take to turn on the heme oxygenase-1 gene? Am J Respir Cell Mol Biol 36:166–174
Kensler TW, Wakabayashi N, Biswal S (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 47:89–116
Lubos E, Loscalzo J, Handy DE (2011) Glutathione Peroxidase-1 in health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 15:1957–1997
Shibahara S (2003) The heme oxygenase dilemma in cellular homeostasis: new insights for the feedback regulation of heme catabolism. Tohoku J Exp Med 200:167–186
Gonzalez-Sanchez E, Perez MJ, Nytofte NS, Briz O, Monte MJ, Lozano E, Serrano MA, Marin JJG (2016) Protective role of biliverdin against bile acid-induced oxidative stress in liver cells. Free Radic Biol Med 97:466–477
Abraham NG, Kappas A (2005) Heme oxygenase and the cardiovascular-renal system. Free Radic Biol Med 39:1–25
Nath KA (2012) Human AKI and heme oxygenase-1. J Am Soc Nephrol 23:971–974
Camara NOS, Soares MP (2005) Heme oxygenase-1 (HO-1), a protective gene that prevents chronic graft dysfunction. Free Radic Biol Med 38:426–435
Amersi F, Shen X-D, Anselmo D, Melinek J, Iyer S, Southard DJ, Katori M, Volk H-D, Busuttil RW, Buelow R, Kupiec-Weglinski JW (2002) Ex vivo exposure to carbon monoxide prevents hepatic ischemia/reperfusion injury through p38 MAP kinase pathway. Hepatology 35:815–823
Battin EE, Brumaghim JL (2009) Antioxidant activity of sulfur and selenium: a review of reactive oxygen species scavenging, glutathione peroxidase, and metal-binding antioxidant mechanisms. Cell Biochem Biophys 55:1–23
Kabel AM (2014) Free radicals and antioxidants: role of enzymes and nutrition. World J Nutr Heal 2:35–38
Modaresi A, Nafar M, Sahraei Z (2015) Oxidative stress in chronic kidney disease. Iran J Kidney Dis 9:165–179
Padayatty SJ, Katz A, Wang Y, Eck P, Kwon O, Lee J-H, Chen S, Corpe C, Dutta A, Dutta SK, Levine M (2003) Vitamin C as an antioxidant: evaluation of its role in disease prevention. J Am Coll Nutr 22:18–35
Pandey KB, Rizvi SI (2009) Plant polyphenols as dietary antioxidants in human health and disease. Oxidative Med Cell Longev 2:270–278
Sansone R, Rodriguez-Mateos A, Heuel J, Falk D, Schuler D, Wagstaff R, Kuhnle GG, Spencer JP, Schroeter H, Merx MW, Kelm M, Heiss C (2015) Cocoa flavanol intake improves endothelial function and Framingham Risk Score in healthy men and women: a randomised, controlled, double-masked trial: the Flaviola Health Study. Br J Nutr 114:1246–1255
Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E (2008) The antioxidant properties of serum albumin. FEBS Lett 582:1783–1787
Prasad AS (2008) Clinical, immunological, anti-inflammatory and antioxidant roles of zinc. Exp Gerontol 43:370–377
Shen H, Oesterling E, Stromberg A, Toborek M, MacDonald R, Hennig B (2008) Zinc deficiency induces vascular pro-inflammatory parameters associated with NF-kappaB and PPAR signaling. J Am Coll Nutr 27:577–587
Holben DH, Smith AM (1999) The diverse role of selenium within selenoproteins: a review. J Am Diet Assoc 99:836–843
Girelli D, Olivieri O, Stanzial AM, Azzini M, Lupo A, Bernich P, Menini C, Gammaro L, Corrocher R (1993) Low platelet glutathione peroxidase activity and serum selenium concentration in patients with chronic renal failure: relations to dialysis treatments, diet and cardiovascular complications. Clin Sci (Lond) 84:611–617
Kashihara N, Haruna Y, Kondeti VK, Kanwar YS (2010) Oxidative stress in diabetic nephropathy. Curr Med Chem 17:4256–4269
Forbes JM, Coughlan MT, Cooper ME (2008) Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57:1446–1454
Galvan DL, Green NH, Danesh FR (2017) The hallmarks of mitochondrial dysfunction in chronic kidney disease. Kidney Int. 10.1016/j.kint.2017.05.034
Granata S, Zaza G, Simone S, Villani G, Latorre D, Pontrelli P, Carella M, Schena FP, Grandaliano G, Pertosa G (2009) Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics 10:388
Ishimoto Y, Inagi R, Yoshihara D, Kugita M, Nagao S, Shimizu A, Takeda N, Wake M, Honda K, Zhou J, Nangaku M (2017) Mitochondrial abnormality facilitates cyst formation in autosomal dominant polycystic kidney disease. Mol Cell Biol. 10.1128/MCB.00337-17
McClelland AD, Herman-Edelstein M, Komers R, Jha JC, Winbanks CE, Hagiwara S, Gregorevic P, Kantharidis P, Cooper ME (2015) miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7. Clin Sci (Lond) 129:1237–1249
Locatelli F, Del Vecchio L, Cavalli A (2009) Inhibition of the renin-angiotensin system in chronic kidney disease: a critical look to single and dual blockade. Nephron Clin Pract 113:c286–c293
Yacoub R, Campbell KN (2015) Inhibition of RAS in diabetic nephropathy. Int J Nephrol Renov Dis 8:29–40
Dou L, Jourde-Chiche N, Faure V, Cerini C, Berland Y, gnat-George F, Brunet P (2007) The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J Thromb Haemost 5:1302–1308
Li MS, Adesina SE, Ellis CL, Gooch JL, Hoover RS, Williams CR (2017) NADPH oxidase-2 mediates zinc deficiency-induced oxidative stress and kidney damage. Am J Phys Cell Phys 312:C47–C55
Kong X, Zhang Y, Wu H, Li F, Zhang D, Su Q (2012) Combination therapy with losartan and pioglitazone additively reduces renal oxidative and nitrative stress induced by chronic high fat, sucrose, and sodium intake. Oxidative Med Cell Longev 2012:856085
Wilson SK (1990) Role of oxygen-derived free radicals in acute angiotensin II-induced hypertensive vascular disease in the rat. Circ Res 66:722–734
Yu M, Kim YJ, Kang D-H (2011) Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin J Am Soc Nephrol 6:30–39
Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL (2001) Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280:E685–E694
Tumur Z, Niwa T (2009) Indoxyl sulfate inhibits nitric oxide production and cell viability by inducing oxidative stress in vascular endothelial cells. Am J Nephrol 29:551–557
Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, Tripepi G, Sesti G, Zoccali C (2005) Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 46:518–523
Ueda S, Yamagishi S, Matsumoto Y, Fukami K, Okuda S (2007) Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clin Exp Nephrol 11:115–121
Correia-Costa L, Sousa T, Morato M, Cosme D, Afonso J, Moura C, Mota C, Areias JC, Guerra A, Schaefer F, Caldas Afonso A, Barros H, Albino-Teixeira A, Azevedo A (2016) Association of myeloperoxidase levels with cardiometabolic factors and renal function in prepubertal children. Eur J Clin Investig 46:50–59
Pecoits-Filho R, Stenvinkel P, Marchlewska A, Heimburger O, Barany P, Hoff CM, Holmes CJ, Suliman M, Lindholm B, Schalling M, Nordfors L (2003) A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl:S172–S176
Gondouin B, Jourde-Chiche N, Sallee M, Dou L, Cerini C, Loundou A, Morange S, Berland Y, Burtey S, Brunet P, Guieu R, Dussol B (2015) Plasma xanthine oxidase activity is predictive of cardiovascular disease in patients with chronic kidney disease, independently of uric acid levels. Nephron 131:167–174
Kohagura K, Tana T, Higa A, Yamazato M, Ishida A, Nagahama K, Sakima A, Iseki K, Ohya Y (2016) Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia. Hypertens Res 39:593–597
Kuo KL, Hung SC, Lee TS, Tarng DC (2014) Iron sucrose accelerates early atherogenesis by increasing superoxide production and upregulating adhesion molecules in CKD. J Am Soc Nephrol 25:2596–2606
Kennedy DJ, Fan Y, Wu Y, Pepoy M, Hazen SL, Tang WH (2014) Plasma ceruloplasmin, a regulator of nitric oxide activity, and incident cardiovascular risk in patients with CKD. Clin J Am Soc Nephrol 9:462–467
Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, Nguyen AT, Thevenin M, Jaudon MC, Zingraff J, Verger C, Jungers P, Descamps-Latscha B (1996) Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 21:845–853
Zachara BA (2015) Selenium and selenium-dependent antioxidants in chronic kidney disease. Adv Clin Chem 68:131–151
Bellisola G, Perona G, Galassini S, Moschini G, Guidi GC (1993) Plasma selenium and glutathione peroxidase activities in individuals living in the Veneto region of Italy. J Trace Elem Electrolytes Health Dis 7:242–244
Courtney AE, McNamee PT, Heggarty S, Middleton D, Maxwell AP (2007) Association of functional haem oxygenase-1 gene promoter polymorphism with polycystic kidney disease and IgA nephropathy. Nephrol Dial Transplant 23:608–611
Chen YH, Hung SC, Tarng DC (2013) Length polymorphism in heme oxygenase-1 and cardiovascular events and mortality in hemodialysis patients. Clin J Am Soc Nephrol
Danielski M, Ikizler TA, McMonagle E, Kane JC, Pupim L, Morrow J, Himmelfarb J (2003) Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy. Am J Kidney Dis 42:286–294
Parham M, Amini M, Aminorroaya A, Heidarian E (2008) Effect of zinc supplementation on microalbuminuria in patients with type 2 diabetes: a double blind, randomized, placebo-controlled, cross-over trial. Rev Diabet Stud 5:102–109
Li B, Tan Y, Sun W, Fu Y, Miao L, Cai L (2013) The role of zinc in the prevention of diabetic cardiomyopathy and nephropathy. Toxicol Mech Methods 23:27–33
Himmelfarb J, McMonagle E (2001) Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int 60:358–363
Ashor AW, Lara J, Mathers JC, Siervo M (2014) Effect of vitamin C on endothelial function in health and disease: a systematic review and meta-analysis of randomised controlled trials. Atherosclerosis 235:9–20
Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS (2000) Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 356:1213–1218
Rassaf T, Rammos C, Hendgen-Cotta UB, Heiss C, Kleophas W, Dellanna F, Floege J, Hetzel GR, Kelm M (2016) Vasculoprotective effects of dietary cocoa flavanols in patients on hemodialysis: a double-blind, randomized, placebo-controlled trial. Clin J Am Soc Nephrol 11:108–118
Nistala R, Whaley-Connell A, Sowers JR (2008) Redox control of renal function and hypertension. Antioxid Redox Signal 10:2047–2089
Drozdz D, Kwinta P, Sztefko K, Kordon Z, Drozdz T, Łątka M, Miklaszewska M, Zachwieja K, Rudziński A, Pietrzyk JA (2016) Oxidative stress biomarkers and left ventricular hypertrophy in children with chronic kidney disease. Oxidative Med Cell Longev 2016:1–8
Garcia-Bello JA, Gómez-Díaz RA, Contreras-Rodríguez A, Talavera JO, Mondragón-González R, Sanchez-Barbosa L, Diaz-Flores M, Valladares-Salgado A, Gallardo JM, Aguilar-Kitsu A, Lagunas-Munoz J, Wacher NH (2014) Carotid intima media thickness, oxidative stress, and inflammation in children with chronic kidney disease. Pediatr Nephrol 29:273–281
Kotur-Stevuljević J, Peco-Antić A, Spasić S, Stefanović A, Paripović D, Kostić M, Vasić D, Vujović A, Jelić-Ivanović Z, Spasojević-Kalimanovska V, Kornic-Ristovski D (2013) Hyperlipidemia, oxidative stress, and intima media thickness in children with chronic kidney disease. Pediatr Nephrol 28:295–303
Chien S-J, Lin I-C, Hsu C-N, Lo M-H, Tain Y-L (2015) Homocysteine and arginine-to-asymmetric dimethylarginine ratio associated with blood pressure abnormalities in children with early chronic kidney disease. Circ J 79:2031–2037
Niwa T (2010) Indoxyl sulfate is a nephro-vascular toxin 28. J Ren Nutr 20:S2–S6
Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, Aydin A, Eyileten T, Ozcan O, Acikel C, Tasar M, Genctoy G, Erbil K, Vural A, Zoccali C (2006) The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 47:42–50
Tyagi N, Sedoris KC, Steed M, Ovechkin AV, Moshal KS, Tyagi SC (2005) Mechanisms of homocysteine-induced oxidative stress. Am J Physiol Hear Circ Physiol 289:H2649–H2656
Shao B, Pennathur S, Pagani I, Oda MN, Witztum JL, Oram JF, Heinecke JW (2010) Modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls, blocks cholesterol efflux by the ABCA1 pathway. J Biol Chem 285:18473–18484
Boaz M, Matas Z, Biro A, Katzir Z, Green M, Fainaru M, Smetana S (1999) Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int 56:1078–1083
Gailly P, Jouret F, Martin D, Debaix H, Parreira KS, Nishita T, Blanchard A, Antignac C, Willnow TE, Courtoy PJ, Scheinman SJ, Christensen EI, Devuyst O (2008) A novel renal carbonic anhydrase type III plays a role in proximal tubule dysfunction. Kidney Int 74:52–61
Andries A, Daenen KEL, Jouret F, Bammens B, Mekhali D, Van Schepdael A (2018) Oxidative stress in autosomal dominant polycystic kidney disease: player and / or early predictor for disease progression? 10.1007/s00467-018-4004-5
Yisireyili M, Shimizu H, Saito S, Enomoto A, Nishijima F, Niwa T (2013) Indoxyl sulfate promotes cardiac fibrosis with enhanced oxidative stress in hypertensive rats. Life Sci 92:1180–1185
Tumur Z, Shimizu H, Enomoto A, Miyazaki H, Niwa T (2010) Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-kappaB activation. Am J Nephrol 31:435–441
Finch JL, Suarez EB, Husain K, Ferder L, Cardema MC, Glenn DJ, Gardner DG, Liapis H, Slatopolsky E (2011) The effect of combining an ACE inhibitor and a VDR activator on glomerulosclerosis, proteinuria and renal oxidative stress in uremic rats. Am J Physiol Ren Physiol 302:F141–149
Kajimoto H, Kai H, Aoki H, Yasuoka S, Anegawa T, Aoki Y, Ueda S, Okuda S, Imaizumi T (2012) Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: new effect of asymmetric dimethylarginine. Kidney Int 81:762–768
Correia-Costa L, Sousa T, Morato M, Cosme D, Afonso J, Areias JC, Schaefer F, Guerra A, Afonso AC, Azevedo A, Albino-Teixeira A (2016) Oxidative stress and nitric oxide are increased in obese children and correlate with cardiometabolic risk and renal function. Br J Nutr 116:805–815
Marcovecchio ML, de Giorgis T, Di Giovanni I, Chiavaroli V, Chiarelli F, Mohn A (2016) Association between markers of endothelial dysfunction and early signs of renal dysfunction in pediatric obesity and type 1 diabetes. Pediatr Diabetes:1–7
Lehners A, Lange S, Niemann G, Rosendahl A, Meyer-Schwesinger C, Oh J, Stahl R, Ehmke H, Benndorf R, Klinke A, Baldus S, Wenzel UO (2014) Myeloperoxidase deficiency ameliorates progression of chronic kidney disease in mice. Am J Physiol Ren Physiol 307:F407–F417
Fukai T, Ushio-Fukai M (2011) Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid Redox Signal 15:1583–1606
Zachara BA, Koterska D, Manitius J, Sadowski L, Dziedziczko A, Salak A, Wasowicz W (2004) Selenium supplementation on plasma glutathione peroxidase activity in patients with end-stage chronic renal failure. Biol Trace Elem Res:15
Bonomini M, Albertazzi A (1995) Selenium in uremia. Artif Organs 19:443–448
Fujishima Y, Ohsawa M, Itai K, Kato K, Tanno K, Turin TC, Onoda T, Endo S, Okayama A, Fujioka T (2011) Serum selenium levels are inversely associated with death risk among hemodialysis patients. Nephrol Dial Transplant 26:3331–3338
Chen Y-H, Kuo K-L, Hung S-C, Hsu C-C, Chen Y-H, Tarng D-C (2014) Length polymorphism in heme oxygenase-1 and risk of CKD among patients with coronary artery disease. J Am Soc Nephrol 25:2669–2677
Daenen KEL, Martens P, Bammens B (2016) Association of HO-1 (GT)n promoter polymorphism and cardiovascular disease: a reanalysis of the literature. Can J Cardiol 32:160–168
Leaf DE, Body SC, Muehlschlegel JD, McMahon GM, Lichtner P, Collard CD, Shernan SK, Fox AA, Waikar SS (2016) Length polymorphisms in heme oxygenase-1 and AKI after cardiac surgery. J Am Soc Nephrol 27:3291–3297
Kim HJ, Vaziri ND (2010) Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Ren Physiol 298:F662–F671
Abo El Gheit R, Emam MN (2016) Targeting heme oxygenase-1 in early diabetic nephropathy in streptozotocin-induced diabetic rats. Physiol Int 103:413–427
Mydlik M, Derzsiova K, Racz O, Sipulova A, Lovasova E (2006) Antioxidant therapy by oral vitamin E and vitamin E-coated dialyzer in CAPD and haemodialysis patients 48. Prague Med Rep 107:354–364
Lobo JC, Torres JP, Fouque D, Mafra D (2010) Zinc deficiency in chronic kidney disease: is there a relationship with adipose tissue and atherosclerosis? Biol Trace Elem Res 135:16–21
Mafra D, Cuppari L, Cozzolino SM (2002) Iron and zinc status of patients with chronic renal failure who are not on dialysis. J Ren Nutr 12:38–41
Esfahani ST, Hamidian MR, Madani A, Ataei N, Mohseni P, Roudbari M, Haddadi M (2006) Serum zinc and copper levels in children with chronic renal failure. Pediatr Nephrol 21:1153–1156
Zwolinska D, Morawska Z, Dobracka A, Miler M, Makulska I, Krol Z (1993) Concentration of selected trace elements in serum and erythrocytes of children with chronic renal failure and am attempt at deficiency correction with animal blood preparation. Wiad Lek 46:116–119
Karamouzis I, Sarafidis PA, Karamouzis M, Iliadis S, Haidich AB, Sioulis A, Triantos A, Vavatsi-Christaki N, Grekas DM (2008) Increase in oxidative stress but not in antioxidant capacity with advancing stages of chronic kidney disease. Am J Nephrol 28:397–404
Nguyen-Khoa T, Massy ZA, Witko-Sarsat V, Thevenin M, Touam M, Lambrey G, Lacour B, Drueke TB, Descamps-Latscha B (1999) Critical evaluation of plasma and LDL oxidant-trapping potential in hemodialysis patients. Kidney Int 56:747–753
Sato E, Tanaka A, Oyama J-I, Yamasaki A, Shimomura M, Hiwatashi A, Ueda Y, Amaha M, Nomura M, Matsumura D, Nakamura T, Node K (2016) Long-term effects of AST-120 on the progression and prognosis of pre-dialysis chronic kidney disease: a 5-year retrospective study. Heart Vessel 31:1625–1632
Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Suzuki T, Ueda Y, Yamagishi S (2011) Oral adsorbent AST-120 ameliorates tubular injury in chronic renal failure patients by reducing proteinuria and oxidative stress generation 1. Metabolism 60:260–264
Hisaki R, Fujita H, Saito F, Kushiro T (2005) Tempol attenuates the development of hypertensive renal injury in Dahl salt-sensitive rats. Am J Hypertens 18:707–713
Nishiyama A, Yoshizumi M, Hitomi H, Kagami S, Kondo S, Miyatake A, Fukunaga M, Tamaki T, Kiyomoto H, Kohno M, Shokoji T, Kimura S, Abe Y (2004) The SOD mimetic tempol ameliorates glomerular injury and reduces mitogen-activated protein kinase activity in Dahl salt-sensitive rats. J Am Soc Nephrol 15:306–315
Tang Y, Yang Q, Lu J, Zhang X, Suen D, Tan Y, Jin L, Xiao J, Xie R, Rane M, Li X, Cai L (2010) Zinc supplementation partially prevents renal pathological changes in diabetic rats. J Nutr Biochem 21:237–246
Soinio M, Marniemi J, Laakso M, Pyorala K, Lehto S, Ronnemaa T (2007) Serum zinc level and coronary heart disease events in patients with type 2 diabetes. Diabetes Care 30:523–528
de Zeeuw D, Akizawa T, Agarwal R, Audhya P, Bakris GL, Chin M, Krauth M, Lambers Heerspink HJ, Meyer CJ, McMurray JJ, Parving HH, Pergola PE, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Warnock DG, Wittes J, Chertow GM (2013) Rationale and trial design of bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes: the occurrence of renal events (BEACON). Am J Nephrol 37:212–222
Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, Krauth M, Ruiz S, Audhya P, Christ-Schmidt H, Wittes J, Warnock DG (2011) Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365:327–336
de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM (2013) Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 369:2492–2503
Chin MP, Reisman SA, Bakris GL, O’Grady M, Linde PG, McCullough PA, Packham D, Vaziri ND, Ward KW, Warnock DG, Meyer CJ (2014) Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. Am J Nephrol 39:499–508
Van Laecke S, Van Biesen W, Vanholder R (2015) The paradox of bardoxolone methyl: a call for every witness on the stand? Diabetes Obes Metab 17:9–14
Jun M, Venkataraman V, Razavian M, Cooper B, Zoungas S, Ninomiya T, Webster AC, Perkovic V (2012) Antioxidants for chronic kidney disease. Cochrane Database Syst Rev 10:CD008176. 10.1002/14651858.CD008176.pub2
Ding W, Wang B, Zhang M, Gu Y (2015) Tempol, a superoxide dismutase-mimetic drug, ameliorates progression of renal disease in CKD mice. Cell Physiol Biochem 36:2170–2182
Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N (2005) Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 20:1048–1056
Foley RN (2010) Clinical epidemiology of cardiovascular disease in chronic kidney disease. J Ren Care 36(Suppl 1):4–8
Groothoff JW, Offringa M, Grootenhuis M, Jager KJ (2017) Long-term consequences of renal insufficiency in children: lessons learned from the Dutch LERIC study. Nephrol Dial Transplant 33:552–560
Mcdonald SP, Craig JC (2004) Long-term survival of children with end-stage renal disease. N Engl J Med 350:2654–2662
Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM (2002) The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62:1524–1538
Fliser D (2005) Asymmetric dimethylarginine (ADMA): the silent transition from an “uraemic toxin” to a global cardiovascular risk molecule. Eur J Clin Investig 35:71–79
Togliatto G, Lombardo G, Brizzi MF (2017) The future challenge of reactive oxygen species (ROS) in hypertension: from bench to bed side. Int J Mol Sci 18
Ali F, Hamdulay SS, Kinderlerer AR, Boyle JJ, Lidington EA, Yamaguchi T, Soares MP, Haskard DO, Randi AM, Mason JC (2007) Statin-mediated cytoprotection of human vascular endothelial cells: a role for Kruppel-like factor 2-dependent induction of heme oxygenase-1. J Thromb Haemost 5:2537–2546
Bertrand ME (2004) Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. Curr Med Res Opin 20:1559–1569
El-Mesallamy HO, Abdel Hamid SG, Gad MZ (2008) Oxidative stress and asymmetric dimethylarginine are associated with cardiovascular complications in hemodialysis patients: improvements by L-arginine intake. Kidney Blood Press Res 31:189–195
Fliser D, Kielstein JT, Haller H, Bode-Boger SM (2003) Asymmetric dimethylarginine: a cardiovascular risk factor in renal disease? Kidney Int Suppl:S37–S40
Maas R, Xanthakis V, Polak JF, Schwedhelm E, Sullivan LM, Benndorf R, Schulze F, Vasan RS, Wolf PA, Boger RH, Seshadri S (2009) Association of the endogenous nitric oxide synthase inhibitor ADMA with carotid artery intimal media thickness in the Framingham Heart Study offspring cohort. Stroke 40:2715–2719
Speer T, Rohrer L, Blyszczuk P, Shroff R, Kuschnerus K, Kränkel N, Kania G, Zewinger S, Akhmedov A, Shi Y, Martin T, Perisa D, Winnik S, Müller MF, Sester U, Wernicke G, Jung A, Gutteck U, Eriksson U, Geisel J, Deanfield J, von Eckardstein A, Lüscher TF, Fliser D, Bahlmann FH, Landmesser U (2013) Abnormal high-density lipoprotein induces endothelial dysfunction via activation of toll-like receptor-2. Immunity 38:754–768
Shroff R, Speer T, Colin S, Charakida M, Zewinger S, Staels B, Chinetti-Gbaguidi G, Hettrich I, Rohrer L, O’Neill F, McLoughlin E, Long D, Shanahan CM, Landmesser U, Fliser D, Deanfield JE (2014) HDL in children with CKD promotes endothelial dysfunction and an abnormal vascular phenotype. J Am Soc Nephrol 25:2658–2668
Kaseda R, Jabs K, Hunley TE, Jones D, Bian A, Allen RM, Vickers KC, Yancey PG, Linton MF, Fazio S, Kon V (2015) Dysfunctional high-density lipoproteins in children with chronic kidney disease. Metabolism 64:263–273
Hadtstein C, Schaefer F (2008) Hypertension in children with chronic kidney disease: pathophysiology and management. Pediatr Nephrol 23:363–371
Hussein G, Bughdady Y, Kandil ME, Bazaraa HM, Taher H (2008) Doppler assessment of brachial artery flow as a measure of endothelial dysfunction in pediatric chronic renal failure. Pediatr Nephrol 23:2025–2030
Wilson AC, Urbina E, Witt SA, Glascock BJ, Kimball TR, Mitsnefes M (2008) Flow-mediated vasodilatation of the brachial artery in children with chronic kidney disease. Pediatr Nephrol 23:1297–1302
Khandelwal P, Murugan V, Hari S, Lakshmy R, Sinha A, Hari P, Bagga A (2016) Dyslipidemia, carotid intima-media thickness and endothelial dysfunction in children with chronic kidney disease. Pediatr Nephrol 31:1313–1320
Mitsnefes MM, Kimball TR, Kartal J, Witt SA, Glascock BJ, Khoury PR, Daniels SR (2006) Progression of left ventricular hypertrophy in children with early chronic kidney disease: 2-year follow-up study. J Pediatr 149:671–675
Mitsnefes M, Flynn J, Cohn S, Samuels J, Blydt-Hansen T, Saland J, Kimball T, Furth S, Warady B (2010) Masked hypertension associates with left ventricular hypertrophy in children with CKD. J Am Soc Nephrol 21:137–144
Kupferman JC, Aronson Friedman L, Cox C, Flynn J, Furth S, Warady B, Mitsnefes M (2014) BP control and left ventricular hypertrophy regression in children with CKD. J Am Soc Nephrol 25:167–174
London G, Covic A, Goldsmith D, Wiecek A, Suleymanlar G, Ortiz A, Massy Z, Lindholm B, Martinez-Castelao A, Fliser D, Agarwal R, Jager KJ, Dekker FW, Blankestijn PJ, Zoccali C (2011) Arterial aging and arterial disease: interplay between central hemodynamics, cardiac work, and organ flow-implications for CKD and cardiovascular disease. Kidney Int Suppl 1:10–12
Vervloet M, Cozzolino M (2017) Vascular calcification in chronic kidney disease: different bricks in the wall? Kidney Int 91:808–817
Chirinos JA (2012) Arterial stiffness: basic concepts and measurement techniques. J Cardiovasc Transl Res 5:243–255
Wilson AC, Mitsnefes MM (2009) Cardiovascular disease in CKD in children: update on risk factors, risk assessment, and management. Am J Kidney Dis 54:345–360
Ma Y, Zhou L, Dong J, Zhang X, Yan S (2015) Arterial stiffness and increased cardiovascular risk in chronic kidney disease. Int Urol Nephrol 47:1157–1164
Choi HY, Park SK, Yun GY, Choi AR, Lee JE, Ha SK, Park HC (2016) Glycated albumin is independently associated with arterial stiffness in non-diabetic chronic kidney disease patients. Medicine 95:e3362
Nishizawa Y, Koyama H, Inaba M (2012) AGEs and cardiovascular diseases in patients with end-stage renal diseases. J Ren Nutr 22:128–133
Rossi M, Campbell KL, Johnson DW, Stanton T, Vesey DA, Coombes JS, Weston KS, Hawley CM, McWhinney BC, Ungerer JPJ, Isbel N (2014) Protein-bound uremic toxins, inflammation and oxidative stress: a cross-sectional study in stage 3-4 chronic kidney disease. Arch Med Res 45:309–317
Gao H, Liu S (2017) Role of uremic toxin indoxyl sulfate in the progression of cardiovascular disease. Life Sci 185:23–29
Annavarajula SK, Dakshinamurty KV, Naidu MU, Reddy CP (2012) The effect of L-arginine on arterial stiffness and oxidative stress in chronic kidney disease. Indian J Nephrol 22:340–346
Schuchardt M, Herrmann J, Tolle M, van der Giet M (2017) Xanthine oxidase and its role as target in cardiovascular disease: cardiovascular protection by enzyme inhibition? Curr Pharm Des 23:3391–3404
MacIsaac RL, Salatzki J, Higgins P, Walters MR, Padmanabhan S, Dominiczak AF, Touyz RM, Dawson J (2016) Allopurinol and cardiovascular outcomes in adults with hypertension. Hypertension 67:535–540
Valko M, Morris H, Cronin MTD (2005) Metals, toxicity and oxidative stress. Curr Top Med Chem 12:1161–1208
Atkinson MA, Warady BA (2017) Anemia in chronic kidney disease. Pediatr Nephrol:1–12
Locatelli F, Barany P, Covic A, De FA, Del VL, Goldsmith D, Horl W, London G, Vanholder R, Van BW (2013) Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European renal best practice position statement. Nephrol Dial Transplant 28:1346–1359
Baracco R, Saadeh S, Valentini R, Kapur G, Jain A, Mattoo TK (2011) Iron deficiency in children with early chronic kidney disease. Pediatr Nephrol 26:2077–2080
Koshy SM, Geary DF (2008) Anemia in children with chronic kidney disease. Pediatr Nephrol 23:209–219
Dursun I, Poyrazoglu HM, Gunduz Z, Ulger H, Yýkýlmaz A, Dusunsel R, Patýroglu T, Gurgoze M (2009) The relationship between circulating endothelial microparticles and arterial stiffness and atherosclerosis in children with chronic kidney disease. Nephrol Dial Transplant 24:2511–2518
Castilla P, Echarri R, Davalos A, Cerrato F, Ortega H, Teruel JL, Lucas MF, Gomez-Coronado D, Ortuno J, Lasuncion MA (2006) Concentrated red grape juice exerts antioxidant, hypolipidemic, and antiinflammatory effects in both hemodialysis patients and healthy subjects. Am J Clin Nutr 84:252–262
